Related Experiment Video
Updated: May 22, 2026
06:00
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
Eribulin: a novel cytotoxic chemotherapy agent
Jessica N Preston1, Meghana V Trivedi
1College of Pharmacy, University of Houston, Houston, TX, USA.
The Annals of Pharmacotherapy
|May 24, 2012
Summary
Eribulin is a novel chemotherapy drug that effectively treats metastatic breast cancer and other advanced cancers. It offers improved survival rates and a manageable safety profile for patients with refractory or resistant disease.
Area of Science:
- Oncology
- Pharmacology
- Cell Biology
Background:
- Eribulin is a synthetic analog of halichondrin B, a natural product with potent anticancer activity.
- It functions as a microtubule dynamics inhibitor, disrupting cancer cell division.
Purpose of the Study:
- To comprehensively review the chemistry, pharmacology, pharmacokinetics, safety, and efficacy of eribulin.
- To assess eribulin's role in treating various advanced cancers.
Main Methods:
- A systematic literature search was conducted using multiple databases and conference abstracts up to December 2011.
- Preclinical and clinical studies evaluating eribulin were reviewed for relevant data.
Main Results:
- Eribulin demonstrated a significant increase in median overall survival (13.1 months vs. 10.6 months) in metastatic breast cancer patients compared to physician's choice therapy.
- The drug has shown activity in non-small cell lung cancer, prostate cancer, urothelial cancer, soft tissue sarcomas, and ovarian cancers.
- Common grade 3/4 adverse events include neutropenia, leukopenia, and peripheral neuropathy.
Conclusions:
- Eribulin is a valuable new cytotoxic chemotherapy agent for cancers resistant to other treatments.
- Its unique mechanism of action and manageable toxicity profile make it a promising therapeutic option.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
01:10Drugs that Destabilize Microtubules
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...